Immunocore Holdings Book Value Per Share Growth & History (IMCR)
Immunocore Holdings's book value per share was $7.52 for fiscal 2025.
View full Immunocore Holdings company overviewImmunocore Holdings annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.52 | $0.31 | +4.33% |
| 2024 | 2024-12-31 | $7.20 | -$0.21 | −2.87% |
| 2023 | 2023-12-31 | $7.42 | $0.37 | +5.25% |
| 2022 | 2022-12-31 | $7.05 | -$1,094.10 | −99.36% |
| 2021 | 2021-12-31 | $1,101.15 | $902.02 | +452.99% |
| 2020 | 2020-12-31 | $199.13 | — | — |
Immunocore Holdings quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.15 | $0.44 | +5.74% |
| Q1 2026 | 2026-03-31 | $7.74 | $0.20 | +2.69% |
| Q4 2025 | 2025-12-31 | $7.52 | $0.31 | +4.33% |
| Q3 2025 | 2025-09-30 | $7.86 | $0.31 | +4.04% |
| Q2 2025 | 2025-06-30 | $7.71 | $0.53 | +7.41% |
| Q1 2025 | 2025-03-31 | $7.54 | $0.35 | +4.89% |
| Q4 2024 | 2024-12-31 | $7.20 | -$0.21 | −2.87% |
| Q3 2024 | 2024-09-30 | $7.55 | — | — |
| Q2 2024 | 2024-06-30 | $7.18 | -$0.04 | −0.51% |
| Q1 2024 | 2024-03-31 | $7.19 | — | — |
| Q4 2023 | 2023-12-31 | $7.42 | $0.37 | +5.25% |
| Q2 2023 | 2023-06-30 | $7.22 | — | — |
| Q4 2022 | 2022-12-31 | $7.05 | — | — |
Immunocore Holdings book value per share trends
Over the last five fiscal years, Immunocore Holdings's book value per share decreased from $199.13 to $7.52, a change of -$191.61. The latest reported quarter, Q2 2026, shows $8.15.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunocore Holdings source filings ↗